Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

A Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors.

Tareen SU, Nicolai CJ, Campbell DJ, Flynn PA, Slough MM, Vin CD, Kelley-Clarke B, Odegard JM, Robbins SH.

Biores Open Access. 2013 Dec 1;2(6):421-30. doi: 10.1089/biores.2013.0037.

PMID:
24380052
[PubMed]
Free PMC Article
2.

Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.

Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, Foley P, Uberla K.

Hum Gene Ther. 2000 Nov 20;11(17):2403-13.

PMID:
11096444
[PubMed - indexed for MEDLINE]
3.

Safety considerations in vector development.

Kappes JC, Wu X.

Somat Cell Mol Genet. 2001 Nov;26(1-6):147-58. Review.

PMID:
12465466
[PubMed - indexed for MEDLINE]
4.

A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct.

Molina RP, Ye HQ, Brady J, Zhang J, Zimmerman H, Kaleko M, Luo T.

Hum Gene Ther. 2004 Sep;15(9):865-77.

PMID:
15353041
[PubMed - indexed for MEDLINE]
5.

Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.

ter Brake O, Berkhout B.

J Gene Med. 2007 Sep;9(9):743-50.

PMID:
17628029
[PubMed - indexed for MEDLINE]
6.

Helper plasmids for production of HIV-1-derived vectors.

Fuller M, Anson DS.

Hum Gene Ther. 2001 Nov 20;12(17):2081-93.

PMID:
11747598
[PubMed - indexed for MEDLINE]
7.

Development of a novel trans-lentiviral vector that affords predictable safety.

Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT, Kappes JC.

Mol Ther. 2000 Jul;2(1):47-55.

PMID:
10899827
[PubMed - indexed for MEDLINE]
Free Article
8.

Analysis of lenti- and trans-lentiviral vector genetic recombination.

Wu X, Wakefield JK, Liu H, Kappes JC.

Dev Biol (Basel). 2001;106:237-48; discussion 249, 253-63.

PMID:
11761237
[PubMed - indexed for MEDLINE]
9.

Design of a trans protease lentiviral packaging system that produces high titer virus.

Westerman KA, Ao Z, Cohen EA, Leboulch P.

Retrovirology. 2007 Dec 28;4:96. doi: 10.1186/1742-4690-4-96.

PMID:
18163907
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.

Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA.

J Virol. 2000 May;74(10):4839-52.

PMID:
10775623
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A third-generation lentivirus vector with a conditional packaging system.

Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L.

J Virol. 1998 Nov;72(11):8463-71.

PMID:
9765382
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Certification assays for HIV-1-based vectors: frequent passage of gag sequences without evidence of replication-competent viruses.

Sastry L, Xu Y, Johnson T, Desai K, Rissing D, Marsh J, Cornetta K.

Mol Ther. 2003 Nov;8(5):830-9.

PMID:
14599817
[PubMed - indexed for MEDLINE]
13.
14.

A new-generation stable inducible packaging cell line for lentiviral vectors.

Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, Radeke R, Bukovsky A, Consiglio A, Naldini L.

Hum Gene Ther. 2001 May 20;12(8):981-97.

PMID:
11387062
[PubMed - indexed for MEDLINE]
15.

A novel approach for producing lentiviruses that are limited to a single cycle of infection.

Evans DT, Bricker JE, Desrosiers RC.

J Virol. 2004 Nov;78(21):11715-25.

PMID:
15479813
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Analysis of partial recombinants in lentiviral vector preparations.

Kuate S, Marino MP, Reiser J.

Hum Gene Ther Methods. 2014 Apr;25(2):126-35. doi: 10.1089/hgtb.2013.015. Epub 2014 Feb 14.

PMID:
24367910
[PubMed - in process]
17.

Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.

Sachdeva G, D'Costa J, Cho JE, Kachapati K, Choudhry V, Arya SK.

J Med Virol. 2007 Feb;79(2):118-26.

PMID:
17177309
[PubMed - indexed for MEDLINE]
18.

Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.

Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B.

J Gene Med. 2004 Sep;6(9):963-73.

PMID:
15352069
[PubMed - indexed for MEDLINE]
19.

Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.

Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang YN, Slepushkin V, Dropulic B.

J Gene Med. 2005 Jun;7(6):818-34. Erratum in: J Gene Med. 2005 Jun;7(6):835.

PMID:
15693055
[PubMed - indexed for MEDLINE]
20.

Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation.

Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN.

J Virol. 1997 Jul;71(7):4892-903.

PMID:
9188551
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk